Boehringer Ingelheim and Cue Biopharma Partner to Develop Next-Generation Treatment for Autoimmune and Inflammatory Diseases

Boehringer Ingelheim and Cue Biopharma, Inc. announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases.